@surftohealth88 Looking closer, it probably wouldn't affect me, because my body (luckily) has managed long-term castrate-sensitivity. The BCL2 inhibitors maybe be able to help the ~10% of patients with a mutation that would otherwise have caused them to develop castrate-resistance faster than expected, in a few months, and may also be helpful (in a different way) after the development of castrate-resistance.

This is another example of how the research community keeps chipping away. There's no one big "Aha!" moment or cure like in the movies; instead, they just keep increasing the number of us who can keep on keeping on with metastatic prostate cancer, bit by bit, until some day we'll be the norm rather than the exception (if we're not there already).